Pharmaceuticals in United Kingdom
21 verified figures for United Kingdom, covering 20 indicators from 3 primary sources. Every figure links to the report it came from.
The short version
Key takeaways
- Median drug approval time in United Kingdom (count) stood at 378 in 2025 (ABPI). ABPI ↗ T2 National
- Pharmaceutical industry investment commitments in United Kingdom totalled 2 billion GBP in 2025–2026 (ABPI). ABPI ↗ T2 National
- Pharmaceutical business enterprise research and development expenditure in United Kingdom totalled 8.7 billion GBP in 2023 (ONS). ONS ↗ T1 Official
- Pharmaceutical direct gross value added in United Kingdom totalled 20.4 billion GBP as of 8 September 2026 (ABPI). ABPI ↗ T2 National
- Pharmaceutical industry employment in United Kingdom stood at 125,000 as of 8 September 2026 (ABPI). ABPI ↗ T2 National
- Branded medicines sales clawback cap in United Kingdom stood at 15% as of 8 September 2026 (ABPI). ABPI ↗ T2 National
- Pharmaceutical share of business enterprise research and development expenditure in United Kingdom stood at 17.4% in 2023 (ONS). ONS ↗ T1 Official
- Clinical trials recruitment setup timeliness rate in United Kingdom stood at 58% as of 8 September 2026 (ABPI). ABPI ↗ T2 National
- Clinical trials regulatory approval timeliness rate in United Kingdom stood at 98% as of 8 September 2026 (ABPI). ABPI ↗ T2 National
- Newer medicines clawback rate in United Kingdom stood at 22.9% in 2025 (ABPI). ABPI ↗ T2 National
The complete table
Pharmaceuticals data for United Kingdom
Every row links to its own page with the full source, verbatim quote and citation.
21 data points across 20 indicators. Each line shows the latest value; open a line for earlier periods and forecasts.
Biopharma, biotech and AI companies countas of 28 Jul 2026470GSKT22026actual→
Branded medicines sales clawback capas of 8 Sep 202615%ABPIT22026actual→
Clinical trial patient recruitment change2022–2025-25%ABPIT22025actual→
Clinical trials recruitment setup timeliness rateas of 8 Sep 202658%ABPIT22026actual→
Clinical trials regulatory approval timeliness rateas of 8 Sep 202698%ABPIT22026actual→
Innovative medicines spending target share of GDPas of 8 Sep 20260.6%ABPIT22026forecast→
Life sciences employmentas of 28 Jul 202622,000GSKT22026actual→
Median drug approval time (count) +1 more 2025378ABPIT22025actual→
New medicines availability rate2021–202433%ABPIT22024actual→
Newer medicines clawback rate202522.9%ABPIT22025actual→
Pharmaceutical and life sciences R&D facility investmentas of 28 Jul 2026400 million GBPGSKT22026estimate→
Pharmaceutical and life sciences R&D facility investment (annual)2026–2029400 million GBPGSKT22029forecast→
Pharmaceutical business enterprise research and development expenditure20238.7 billion GBPONST12023actual→
Pharmaceutical direct gross value addedas of 8 Sep 202620.4 billion GBPABPIT22026actual→
Pharmaceutical industry employmentas of 8 Sep 2026125,000ABPIT22026actual→
Pharmaceutical industry investment commitments2025–20262 billion GBPABPIT22026actual→
Pharmaceutical share of business enterprise research and development expenditure202317.4%ONST12023actual→
Projected pharmaceutical direct gross value added203533.4 billion GBPABPIT22035forecast→
Projected pharmaceutical employment2035200,000ABPIT22035forecast→
Projected pharmaceutical job creationend of 203581,300ABPIT22035forecast→
Primary documents
Sources
| Document | Publisher | Authority tier | Published | Accessed | Locator | Data points |
|---|---|---|---|---|---|---|
| Business enterprise research and development, UK Press release | ONS | T1 Official | — | 17 Sep 2026 | Main points | 2 |
| Green shoots for UK pharma investment, but delivery will decide whether they take root Press release | ABPI | T2 National | — | 17 Sep 2026 | UK competitive weaknesses; UK areas of unrealised potential; Green shoots for UK pharma investment, but delivery will decide whether they take root | 15 |
| GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK Press release | GSK | T2 National | — | 17 Sep 2026 | GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK | 4 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
All 21 collected records for United Kingdom are published as verified.
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. Each figure's own page carries APA, MLA, Chicago and BibTeX citations naming its original publisher.
StatOrigin. (2026). Pharmaceuticals in United Kingdom: statistics. Retrieved from https://statorigin.org/industries/pharmaceuticals/united-kingdom